Obermatt
See Similar Stocks →

Mayne Pharma

ASX:MYX · AU000000MYX0
PharmaceuticalsSmall

360

55
Profit price79
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit97
Price/Book100
Return on Capital40
Cash Return on Capital45
Return on Equity45
EBIT Margin33
Gross Profitability62
Accruals77
Owner Earnings Margin48
Sales growth1
Profit growth6
Reinvestment7
Price momentum7
Debt load79
Refinancing51
Debt Payback1
Liquidity18
Analyst ratings100
Opinion Changes50
Price Target Upside86
Market mood1
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mayne Pharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryAustralia
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeASX
Founded2005
Employees443
Websitemaynepharma.com
ISINAU000000MYX0
Last UpdateApr 2, 2026
Indices
ASX 300 (Australia)
Themes
Women's HealthDermatologyBiotechnologyHealth CarePharmaceutical

Description

Mayne Pharma Group Limited (Mayne Pharma) operates as a global specialty pharmaceutical company focused on the development, manufacturing, and commercialization of branded and generic pharmaceuticals to meet patients’ unmet needs. The company offers…

Analysis

Middle-of-the-road

Mayne Pharma Group Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
64
2023202420252026

All-time high

92

Jan 2024

All-time low

33

Jan 2023

Average rank

60

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
82
87
93
Price/Earnings
91
86
86
24
Price/Book
100
59
75
95
Dividend Yield
1
1
1
100
Value (overall)
94
40
54
89

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mayne Pharma with its peers
Towa Pharmaceutical
TYO:4553
50
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Korea United Pharm
KSC:033270
90
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Lotus Pharmaceutical
TAI:1795
19
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hanmi Pharmaceutical
KSC:128940
76
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →